ERIS LIFESCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 907.7 INR | -0.03% |
|
+3.62% | -0.25% |
| 07:49am | Eris Lifesciences Posts Gains in Fiscal Q4 Consolidated Net Profit | MT |
| 21/05 | Eris Lifesciences Gets Board Nod to Raise Up to INR12.50 Billion Via Bond Sale | MT |
Valuation
| Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 88,687 | 50,089 | 82,147 | 93,615 | 77,801 | 1,23,490 | - | - |
| Enterprise Value (EV) 1 | 88,687 | 50,089 | 82,147 | 93,615 | 85,984 | 1,14,719 | 1,48,733 | 1,30,419 |
| P/E ratio | 30.5 x | 17.1 x | 23.1 x | 23 x | 20.4 x | 29.3 x | 30.8 x | 22.5 x |
| Yield | - | 0.62% | 0.91% | 0.87% | 1.28% | 0.79% | 0.47% | 0.95% |
| Capitalization / Revenue | 9.03 x | 4.66 x | 6.78 x | 6.95 x | 4.62 x | 5.71 x | 4.19 x | 3.97 x |
| EV / Revenue | 9.03 x | 4.66 x | 6.78 x | 6.95 x | 5.1 x | 5.71 x | 5.04 x | 4.19 x |
| EV / EBITDA | 25.7 x | 13.6 x | 19.1 x | 19.3 x | 16 x | 17 x | 14.4 x | 11.5 x |
| EV / FCF | 47.9 x | 41.8 x | 23.5 x | 36.4 x | -15.6 x | -399 x | -14.1 x | 19.9 x |
| FCF Yield | 2.09% | 2.39% | 4.26% | 2.75% | -6.39% | -0.25% | -7.1% | 5.02% |
| Price to Book | 7.71 x | 3.86 x | 5.21 x | 4.91 x | 3.54 x | 4.9 x | 4.24 x | 3.61 x |
| Nbr of stocks (in thousands) | 1,37,520 | 1,35,781 | 1,35,781 | 1,35,930 | 1,35,992 | 1,36,047 | - | - |
| Reference price 2 | 644.9 | 368.9 | 605.0 | 688.7 | 572.1 | 908.0 | 908.0 | 908.0 |
| Announcement Date | 21/05/19 | 02/06/20 | 13/05/21 | 03/05/22 | 17/05/23 | 21/05/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9,822 | 10,741 | 12,119 | 13,470 | 16,851 | 20,091 | 29,494 | 31,105 |
| EBITDA 1 | 3,449 | 3,683 | 4,306 | 4,850 | 5,367 | 6,748 | 10,336 | 11,318 |
| EBIT 1 | 3,086 | 3,180 | 3,876 | 4,202 | 4,197 | 4,922 | 7,429 | 8,627 |
| Operating Margin | 31.42% | 29.61% | 31.98% | 31.2% | 24.9% | 24.5% | 25.19% | 27.73% |
| Earnings before Tax (EBT) 1 | 3,174 | 3,315 | 3,945 | 4,422 | 4,046 | 4,312 | 5,534 | 7,417 |
| Net income 1 | 2,908 | 2,963 | 3,551 | 4,061 | 3,822 | 3,920 | 4,086 | 5,521 |
| Net margin | 29.61% | 27.59% | 29.3% | 30.15% | 22.68% | 19.51% | 13.85% | 17.75% |
| EPS 2 | 21.13 | 21.58 | 26.14 | 29.88 | 28.07 | 28.79 | 29.46 | 40.40 |
| Free Cash Flow 1 | 1,850 | 1,198 | 3,496 | 2,572 | -5,497 | -336 | -10,554 | 6,548 |
| FCF margin | 18.84% | 11.16% | 28.85% | 19.1% | -32.62% | -1.71% | -35.78% | 21.05% |
| FCF Conversion (EBITDA) | 53.63% | 32.54% | 81.19% | 53.04% | - | - | - | 57.85% |
| FCF Conversion (Net income) | 63.62% | 40.44% | 98.44% | 63.34% | - | - | - | 118.61% |
| Dividend per Share 2 | - | 2.287 | 5.500 | 6.010 | 7.350 | 7.155 | 4.250 | 8.667 |
| Announcement Date | 21/05/19 | 02/06/20 | 13/05/21 | 03/05/22 | 17/05/23 | 21/05/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,104 | 2,782 | 3,437 | 3,597 | 3,322 | 3,059 | 3,986 | 4,605 | 4,233 | 4,028 | 4,666 | 5,094 | 4,825 | 5,130 |
| EBITDA 1 | 1,072 | 945.2 | 1,265 | 1,398 | 1,217 | 969 | 1,292 | 1,514 | 1,372 | 1,189 | 1,697 | 1,819 | 1,740 | 1,788 |
| EBIT | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | 993 | 847.3 | 1,171 | 1,308 | 1,090 | 853.4 | 1,013 | 1,209 | 1,065 | 759 | 1,125 | 1,288 | 1,195 | 1,102 |
| Net income 1 | 901.5 | 682.5 | 1,067 | 1,184 | 1,008 | 803 | 945.8 | 1,203 | 1,019 | 654.2 | 948.6 | 1,088 | 1,022 | 912.4 |
| Net margin | 29.04% | 24.53% | 31.04% | 32.92% | 30.34% | 26.25% | 23.73% | 26.12% | 24.07% | 16.24% | 20.33% | 21.36% | 21.18% | 17.78% |
| EPS | - | - | - | - | - | - | - | - | - | - | - | 7.880 | - | 6.600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 28/01/21 | 13/05/21 | 29/07/21 | 29/10/21 | 28/01/22 | 03/05/22 | 05/08/22 | 20/10/22 | 17/01/23 | 17/05/23 | 07/08/23 | - | - | - |
1INR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 8,183 | 10,438 | 25,243 | 6,929 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | 1.524 x | 1.472 x | 2.442 x | 0.6122 x |
| Free Cash Flow 1 | 1,850 | 1,198 | 3,496 | 2,572 | -5,497 | -336 | -10,554 | 6,548 |
| ROE (net income / shareholders' equity) | 28.9% | 24.2% | 24.7% | 23.3% | 18.6% | 17.8% | 14.2% | 17.6% |
| ROA (Net income/ Total Assets) | - | 19.1% | - | - | 12.9% | 14.8% | 17.6% | 18.9% |
| Assets 1 | - | 15,535 | - | - | 29,697 | 27,797 | 23,209 | 29,277 |
| Book Value Per Share 2 | 83.70 | 95.50 | 116.0 | 140.0 | 161.0 | 185.0 | 214.0 | 251.0 |
| Cash Flow per Share 2 | - | - | 27.60 | 27.80 | 21.40 | 44.70 | 47.60 | 56.60 |
| Capex 1 | 374 | 1,513 | 258 | 1,210 | 8,414 | 7,142 | 15,240 | 1,972 |
| Capex / Sales | 3.81% | 14.09% | 2.13% | 8.99% | 49.93% | 36.26% | 51.67% | 6.34% |
| Announcement Date | 21/05/19 | 02/06/20 | 13/05/21 | 03/05/22 | 17/05/23 | 21/05/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
907.7
INR
Average target price
1,079
INR
Spread / Average Target
+18.86%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.25% | 1.48B | |
| +36.83% | 723B | |
| +32.22% | 598B | |
| -2.28% | 364B | |
| +20.22% | 331B | |
| +3.54% | 288B | |
| +16.36% | 244B | |
| +9.87% | 210B | |
| -5.40% | 208B | |
| +8.92% | 169B |
- Stock Market
- Equities
- ERIS Stock
- Financials Eris Lifesciences Limited